BUZZ-Ionis shares fall after lowering sales forecast for Tryngolza, impacting SOBI stock price

November 10 - **Shares of Swedish biopharmaceutical company SOBI (SOBIV.ST) fell by about 2%

** Pareto Securities analyst Filip Wiberg attributed the share price movement to a report released Monday by Ionis

** Ionis IONS.O lowered its 2026 sales forecast for the severe hypertriglyceridemia drug Tryngolza (link) from the previous estimate of $100 million to $110 million down to $50 million

** Wiberg added that Tryngolza is seen as a significant growth driver for SOBI from 2027 onward and beyond

**Deutsche Bank (DB) downgraded the stock from "Buy" to "Hold", citing Ionis's actions on Tryngolza

** The bank said that although the business has maintained strong double-digit growth and the overall situation is "robust", the weak launch performance of "Tryngolza" remains a negative factor

(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may be inaccurate or may not capture the necessary context, Reuters does not guarantee the accuracy of automated translation text and provides it solely for readers’ convenience. Reuters is not responsible for any damage or loss resulting from the use of automated translation features.)